Effects of niacin versus ezetimibe on serum paraoxygenase and arylesterase activities of HDL cholesterol in patients with or at risk for CAD

Trial Profile

Effects of niacin versus ezetimibe on serum paraoxygenase and arylesterase activities of HDL cholesterol in patients with or at risk for CAD

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2012

At a glance

  • Drugs Ezetimibe (Primary) ; HMG-CoA reductase inhibitors; Niacin
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Apr 2012 New trial record
    • 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top